A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB AS ADJUVANT TREATMENT FOLLOWING COMPLETE RESECTION AND PLATINUM-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH EARLY-STAGE NON-SMALL CELL LUNG CANCER WITH A HIGH RISK OF RECURRENCE

被引：0
|
作者：
Miguel, Silva L. [1 ]
Pinheiro, B. [2 ]
Carvalho, P. [1 ]
Jovanoski, N. [3 ]
Belleli, R. [3 ]
Abogunrin, S. [3 ]
Alves, P. [1 ,4 ]
Araujo, A. [5 ]
Barata, F. [6 ]
Hespanhol, V [7 ]
da Luz, R. [8 ]
Borges, M. [9 ]
机构：
[1] IQVIA Portugal, Lisbon, Portugal
[2] IQVIA Portugal, Oeiras, Portugal
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Ctr Hosp Univ Lisboa Norte, Lisbon, Portugal
[5] Ctr Hosp Univ Santo Antonio, Porto, Portugal
[6] Ctr Hosp & Univ Coimbra, Coimbra, Portugal
[7] Ctr Hosp Univ S Joao, Porto, Portugal
[8] Ctr Hosp & Univ Lisboa Cent, Lisbon, Portugal
[9] Univ Lisbon, Lab Farmacol Clin & Terapeut, Fac Med, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE78
引用
收藏
页码：S65 / S65
页数：1
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB AS ADJUVANT TREATMENT (MONOTHERAPY) FOR ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER FOLLOWING RESECTION AND PLATINUM-BASED CHEMOTHERAPY IN GREECE
    Nomikos, N.
    Naoum, P.
    Karampli, E.
    Jovanoski, N.
    Kakouros, M.
    Sideri-Papagianni, G.
    Kyriopoulos, I
    Pavi, E.
    Athanasakis, K.
    VALUE IN HEALTH, 2023, 26 (12) : S186 - S187
  • [2] A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT PEMBROLIZUMAB IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE (STAGES IB-III) NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING COMPLETE RESECTION AND PLATINUM-BASED CHEMOTHERAPY
    Draganigos, A.
    Nguyen, S.
    Skroumpelos, A.
    Iliopoulou, E.
    Mylonas, C.
    Karokis, A.
    VALUE IN HEALTH, 2024, 27 (12) : S92 - S92
  • [3] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer
    Inamura, Kentaro
    JAMA ONCOLOGY, 2021, 7 (04) : 637 - 638
  • [4] Adjuvant chemotherapy for early-stage non-small cell lung cancer
    Visbal, AL
    Leighl, NB
    Feld, R
    Shepherd, FA
    CHEST, 2005, 128 (04) : 2933 - 2943
  • [5] Adjuvant chemotherapy in early-stage non-small cell lung cancer
    Dômont, J
    Soria, JC
    Le Chevalier, T
    SEMINARS IN ONCOLOGY, 2005, 32 (03) : 279 - 283
  • [6] Adjuvant Chemotherapy in Elderly Patients with Early-stage Non-small Cell Lung Cancer
    Kefeli, Umut
    Kaymaz, Samet
    Aydin, Dincer
    Isik, Deniz
    Cabuk, Devrim
    Sonkaya, Alper
    Acikgoz, Ozgur
    Isik, Ulas
    Ozden, Ercan
    Uygun, Kazim
    BEZMIALEM SCIENCE, 2019, 7 (04): : 265 - 270
  • [7] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer Reply
    Pathak, Ranjan
    Boffa, Daniel J.
    JAMA ONCOLOGY, 2021, 7 (04) : 638 - 638
  • [8] Adjuvant Chemotherapy for Older Patients With Early-Stage Non-Small Cell Lung Cancer
    Ganti, A.
    Williams, C.
    Gajra, A.
    Kelley, M. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S12 - S13
  • [9] Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
    Tian, Wentao
    Niu, Lishui
    Wang, Ziqi
    Lu, Ruoyu
    Xiao, Gang
    Deng, Fuxing
    Tanzhu, Guilong
    Zhou, Rongrong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [10] A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis.
    Stenehjem, David D.
    Bellows, Brandon Kyle
    Kaldate, Rajesh R.
    Jones, Joshua Timothy
    Siebert, Uwe
    Brixner, Diana I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345